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Abstract: Germline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent
in prostate cancer than previously recognized, with BRCA2 as the most commonly altered gene.
Germline mutations in BRCA2 have been linked to poor prognosis when patients are managed under
the protocols currently approved for prostate cancer. The impact of germline mutations in other DDR
genes beyond BRCA2 remain unclear. Importantly, a quarter of prostate cancer patients identified as
germline mutation carriers lack a family history of cancer. The clinical implications of somatic DDR
defects are yet to be elucidated. Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based
chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and
BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer. Here,
we summarize the available evidence regarding the prevalence of somatic and germline DDR defects
in prostate cancer; their association with clinical outcomes; the trials assessing the efficacy of new
therapies that exploit DDR defects in prostate cancer and briefly discuss some uncertainties about the
most appropriate management for these patients.
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1. Introduction
Alterations in the DNA damage repair (DDR) pathways have only recently been recognized
as a major hallmark of prostate cancer. Next-generation sequencing studies have revealed that
about 10% of primary tumors and 25% of metastases from prostate cancer harbor DDR defects [1,2]
with BRCA2 aberrations consistently described as the most common event. Germline deleterious
mutations in DDR genes are present in 8–16% of metastatic prostate cancer patients [1,3,4], a prevalence
significantly higher than previously recognized. Inherited BRCA2 mutations that impair the gene
function have been described in 3–5% of patients with advanced prostate cancer [3,4]. These BRCA2
mutations have been associated with more aggressive disease and poor clinical outcomes [5–9],
but the prognostic implications of other DDR genes are less well established. On the other hand,
there is strong emerging evidence that some germline and somatic DDR defects may predict the
response to poly-ADP ribose polymerase (PARP) inhibitors and platinum-based chemotherapy in
prostate cancer [10–13]. These findings make genetic testing attractive not only for risk stratification,
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but also for treatment selection. The decrease in the cost of sequencing and the broad access to these
platforms will presumably result in an increased number of prostate cancer patients identified as
DDR mutation carriers, who could benefit from appropriate genetic counseling and personalized
management and therapies.
2. Alterations in DNA Repair Genes Are Common in Prostate Cancer
Several recent studies cataloguing the genetic landscape of prostate cancer have shown that a
significant proportion of cases harbor aberrations in the DDR genes [1,2,14–17].
Nineteen per cent of the 333 primary prostate tumors sequenced by The Cancer Genome Atlas
Research Network (TCGA) had deleterious germline or somatic aberrations in the DDR genes including
BRCA2, BRCA1, CDK12, ATM, FANCD2, and RAD51C [16]. However, all six cases with germline BRCA2
mutations presented the same variant, p.K3326* (c.9976A>T), arguably deleterious. The International
Stand Up to Cancer/Prostate Cancer Foundation/American Association for Cancer Research Prostate
Cancer Team identified alterations in the DDR genes in 23% of the 150 metastatic biopsies analyzed [1].
BRCA2 was altered in 13% of samples followed by ATM (7.3%), MSH2 (2%), and BRCA1, FANCA, MLH1,
RAD51B, and RAD51C (0.3%). A larger study that analyzed 680 primary tumors and 333 metastatic
samples including cases from the previously mentioned studies, identified germline and/or somatic
DDR defects in 10% and 27% of the primary and metastatic samples, respectively [2].
The study by Robinson et al. [1] provided the first evidence suggesting that germline mutations in
DDR genes known to be linked to increased cancer risk were present in metastatic prostate cancer with
a higher prevalence than previously recognized. Unexpectedly, 8% of the DDR mutations identified in
the metastatic samples were in the germline. In 2016, a study of germline mutations in 692 men with
metastatic prostate cancer revealed that 11.8% of them harbored a germline mutation in one of the
20 DDR genes associated with the cancer-predisposition syndromes analyzed [3] (Table 1). The fact that
this prevalence was significantly higher than the 5% identified in men with localized disease and the
3% in the general population [3,16], suggests that such events may predispose men to aggressive forms
of the disease. The PROREPAIR-B study screened 419 unselected men in Spain with metastatic prostate
cancer for germline mutations in 107 genes (Table 1) and found that 7.4% of the participants carried
inherited mutations in any of the genes studied by Pritchard et al. [3,4]. The variation in prevalence
was likely to due to the different genetic background of both populations. In the series reported by
Pritchard et al., Ashkenazi founder mutations BRCA1 c.5266dupC and BRCA2 c.5946delT accounted
for 66% and 24% of the mutations identified in BRCA1 and BRCA2, respectively. Similarly, the Eastern
European founder mutation CHEK2 c.1100del represented 50% of all mutations in CHEK2. These three
mutations, which accounted for 22% of all mutations, are very rare in the Spanish population included
in PROREPAIR-B [18,19] and no carriers of these variants were identified. However, BRCA2 remained
the most frequently mutated gene in this second study, although with a lower prevalence (3.3%) than
the one previously reported (5.3%). It is also possible that in the time elapsed between the two studies,
some variants initially considered as likely pathogenic have been reclassified as variants of unknown
significance, resulting in a lower prevalence of pathogenic mutations in the second study. Screening
studies in groups with different genetic backgrounds and an accurate classification of genetic variants
are needed for a more precise estimation of the prevalence of germline mutations in DDR genes
across populations.
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Table 1. DDR genes screened for germline mutations in mCRPC studies mentioned in this review.
Pritchard et al. [3] and Mateo et al. [20]
ATM ATR BAP1 BARD1 BRCA1
BRCA2 BRIP1 CHEK2 FAM175A GEN1
MLH1 MRE11A MSH2 MSH6 NBN
PALB2 PMS2 RAD51C RAD51D XRCC2
Castro et al. [4]
APEX1 ERCC4 GTF2H5 NTHL1 RBBP8
APEX2 ERCC5 KIAA0415 OGG1 RPA1
APLF ERCC6 LIG4 PALB2 RPA2
ATM ERCC8 MBD4 PARP1 RPA3
ATR FAAP20 MLH1 PARP2 SLX1A
BARD1 FAAP24 MLH3 PARP3 SLX1B
BRCA1 FAM175B MMS19 PMS1 SLX4
BRCA2 FANCA MNAT1 PMS2 SMUG1
BRIP1 FANCB MPG PNKP TDG
CDK7 FANCC MRE11A PRKDC UNG
CDK12 FANCD2 MSH2 RAD9A XAB2
CHEK1 FANCE MSH3 RAD17 XPA
CHEK2 FANCF MSH4 RAD23A XPC
DCLRE1C FANCG MSH5 RAD23B XRCC1
DDB1 FANCI MSH6 RAD50 XRCC2
DMC1 FANCL MUS81 RAD51 XRCC3
EME1 FANCM MUTYH RAD51B XRCC4
EME2 GEN1 NBN RAD51C XRCC5
EPCAM GTF2H1 NEIL1 RAD51D XRCC6
ERCC1 GTF2H2 NEIL2 RAD52
ERCC2 GTF2H3 NEIL3 RAD54B
ERCC3 GTF2H4 NHEJ1 RAD54L
Antonarakis et al. [21]
ATM CDK12 FAM175A GEN1 PIF1
ATR CENPQ FAM175B HDAC2 PMS2
BAP1 CHEK1 FANCA MLH1 RAD51
BARD1 CHEK2 FANCC MLH3 RAD51B
BLM EPCAM1 FANCD2 MRE11A RAD51C
BRAP ERCC1 FANCE MSH2 RAD51D
BRCA1 ERCC2 FANCF MSH6 RAD54L
BRCA2 ERCC3 FNCG MUTYH RDM1
BRIP1 ERCC4 FANCI NBN TP53
CDH1 ERCC6 FANCL PALB2 XRCC2
Annala et al. [22]
ATM ERCC1 FANCA FANCG RAD51B
ATR ERCC2 FANCC MLH1 RAD51C
BRCA1 ERCC3 FANCD2 MSH2
BRCA2 ERCC4 FANCE MSH6
CDK12 ERCC5 FANCF PALB2
3. Impact of BRCA Mutations on Clinical Outcomes and Response to Treatment
in Prostate Cancer
3.1. Management of Localized Disease
A range of management options is available for men with localized prostate cancer. The criteria
to consider active surveillance, radiotherapy, or radical prostatectomy for the general population
are usually based on several factors including PSA levels at diagnosis, Gleason score, tumor stage,
performance status, life expectancy, and patient preference [23,24]. BRCA1 and BRCA2 mutation
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carriers with localized disease are usually managed under the same general protocols as no definitive
evidence has demonstrated that they should be treated otherwise.
Active surveillance can be an adequate management strategy for men with low-risk localized
prostate cancer unlikely to affect the patient’s life expectancy in the absence of treatment [24].
It consists of regular PSA monitoring and MRI, allowing curative intervention for those patients
that experience disease progression. The poor outcomes associated with BRCA2-related prostate
tumors have discouraged physicians to recommend active surveillance to eligible carriers although
evidence to support this decision has only been provided recently. A report analyzing the outcomes of
1211 men undergoing active surveillance including 11 BRCA1, 11 BRCA2, and 5 ATM germline carriers
showed that tumors in BRCA2 carriers were more likely to present a tumor grade reclassification
requiring radical treatment when compared to non-carriers. The tumor staging upgrade incidence at
2-, 5- and 10- years was 27%, 50%, and 78% in BRCA2 carriers compared to 10%, 22% and 40% in non-
carriers (p = 0.001) [25].
No conclusive data are available regarding whether alterations in BRCA2 or other DDR genes
are relevant in selecting between curative treatment options (radical prostatectomy or radiotherapy).
The only reported data comes from a retrospective study that analyzed the outcomes of 1200 patients
with localized disease including 18 BRCA1 and 49 BRCA2 carriers, and reported that 89% and 67%
of BRCA surgically treated were free from metastasis at 5 and 10 years, respectively, when compared
to 97% and 91% of non-carriers (p = 0.024). For those treated with radiotherapy, the difference was
even greater as only 57% and 39% of BRCA1/2 carriers were free from metastasis at 5 and 10 years,
respectively, compared to 91% and 80% of non-carriers (p < 0.001) [9].
One could be tempted to assume that surgery is a better approach for mutation carriers, however,
this conclusion cannot be based on this study. The two treatment cohorts were not balanced due
to the fact that patients treated with radiotherapy (both carriers and non-carriers) presented with
more advanced disease than those men surgically treated, and a direct comparison of the two groups
was not performed. Nonetheless, these data raise the question of whether adjuvant treatments
may be beneficial for BRCA1/2 carriers. Androgen deprivation therapy (ADT) is routinely added to
radiotherapy for localized disease. No evidence has been produced to support a different ADT scheme
in carriers, but since androgen deprivation seems to downregulate both homologous recombination
(HR) [26] and non-homologous End Joining (NHEJ) [27,28], prolonged ADT or the addition of new
androgen receptor signaling inhibitors (ARSI) such as abiraterone, enzalutamide, or apalutamide,
might be of benefit for those carriers undergoing radiotherapy. Adjuvant chemotherapy with docetaxel
following radiotherapy in unselected patients with high-risk disease improves relapse-free survival,
but the benefit in metastasis free survival and overall survival is less clear [29]. Several trials are
currently ongoing that would provide definite data on the impact of adjuvant chemotherapy or
ARSI on metastasis free survival and overall survival. To our knowledge, outcome analyses in these
studies have not been planned to be stratified by BRCA and/or DDR status. However, if conducted,
such analyses would provide an insight into the benefit of different adjuvant schemes and guide future
clinical trials in this population.
3.2. Management of Metastatic Prostate Cancer
After failure of the primary treatment, the disease is usually managed with long-term androgen
deprivation therapy (ADT). Disease progression on continuous ADT is termed castration resistant
prostate cancer (CRPC). The PROREPAIR-B study has shown that germline BRCA2 mutation carriers
become resistant to ADT faster than non-carriers. In the study, the median time from continuous ADT
initiation to CRPC was 28 months for non-carriers when compared to 13.2 months in BRCA2 carriers
(p = 0.05) [4].
PROREPAIR-B has been the first prospective study to address the impact of germline mutations
in BRCA1, BRCA2, and other DDR genes in patients with metastatic CRPC (mCRPC) [4]. Although the
10-month difference in cause specific survival (CSS) between ATM, BRCA1, BRCA2, PALB2 mutation
Cancers 2019, 11, 352 5 of 15
carriers, and non-carriers (33.2 vs. 23) was not statistically significant (p = 0.264), the study showed that
CSS from mCRPC was halved in BRCA2 carriers when compared to non-carriers (17 vs. 33, p = 0.027).
The difference remained significant when the BRCA2 carriers were compared to other germline DDR
carriers (median 33.8 months, p = 0.048). Multivariate analyses identified BRCA2 as an independent
prognostic factor for CSS in mCRPC (HR 2.11, 95% CI 1.06–4.18). Importantly, none of the carriers
in this series had received a Poly ADP-ribose polymerase (PARP) inhibitor and/or platinum-based
chemotherapy, which may have had a confounding effect on survival.
Analysis of the response to taxanes and ARSIs in the PROREPAIR-B study showed no difference
in the response rates based on carrier status [4]. However, the duration of the responses tended to
be shorter in carriers, particularly in those harboring BRCA2 mutations. Importantly, the outcomes
of BRCA2 carriers who received abiraterone or enzalutamide as first-line treatment did not differ
from that of non-carriers. Conversely, BRCA2 carriers treated with the taxane-ASI sequence had
significantly worse CSS (median 28.4 vs. 10.7 months, p = 0.0003; HR:4.16, 95% CI 1.80–9.62) and the
progression-free survival from the first systemic therapy until progression on the second systemic
therapy (PFS2) was also shorter (median 17.1 vs. 8.6 months, p < 0.0001; HR:8.16 95% CI 3.60–18.49)
than in non-carriers who received the same treatment [30]. No biomarker has been identified to date
for selecting one therapy over another in the setting of advanced prostate cancer. If these preliminary
results are confirmed, the determination of germline BRCA2 status would be of assistance for the
selection of the first line of treatment in mCRPC.
The observations described above may contribute to explain the contradictory results previously
reported by three retrospective series that have evaluated the response of germline DDR carriers to
abiraterone and enzalutamide. Annala et al. [22] analyzed the outcomes of 176 metastatic CRPC
patients including 22 DDR carriers (16 BRCA2) (Table 1), and found that the progression free
survival (PFS) of DDR carriers on first-line ASI was significantly shorter than that of non-carriers
(3.3 vs. 6.2 months, p = 0.01). The poor PFS could be related to the high tumor burden in the patients
included as reflected by the high levels of circulating tumor DNA (ctDNA) reported (>30%). Authors
also remarked on the great heterogeneity observed in PFS, with some DDR carriers benefiting from
ARSIs for >2 years. This was the main observation of the second study by Antonarakis et al. [21], who
observed a trend toward a more prolonged PFS in mutation carriers when compared to non-carriers (15
vs. 10.8 months, p = 0.090) treated with ARSi. Interestingly, they also identified previous chemotherapy
as a factor associated with worse PFS and CSS, but did not analyze whether this affects the same to
carriers and non-carriers. The third study is the retrospective analysis of patients from the landmark
publication by Pritchard et al. in 2016 [20]. The authors reported the outcomes of 330 non-carriers
and 60 DDR carriers (including 37 BRCA2) and found no association between mutation status and the
response or duration of treatment to the first ARSI or taxane administered.
The clinical implications of somatic mutations in BRCA2 and other DDR genes have not been well
characterized yet and there is no evidence of whether these patients may respond differently to the
treatment options currently available.
4. Mutations in BRCA and Other DNA Repair Genes as a Potential Target for Platinum-Based
Chemotherapy and PARP Inhibitors in Prostate Cancer
Specific treatment strategies for patients with somatic and/or germline mutations in DNA repair
genes could be obtained from research in other tumor types frequently associated with these events
such as breast and ovarian cancers. Platinum-based chemotherapy has been proven to be an effective
treatment for BRCA1 and BRCA2 mutated breast [31,32] and ovarian cancers [33] as these compounds
generate DNA cross-links that cannot be easily resolved with an impaired homologous recombination
(HR). In standard protocols for prostate cancer, platinum-based chemotherapy is only used when
neuroendocrine differentiation has occurred as phase III trials in mCRPC failed to show any benefit
in unselected population [34]. However, several retrospective reports have suggested that BRCA2
mutated prostate cancer may be highly sensitive to this therapy [10–12]. In a retrospective analysis of
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141 men with mCRPC treated at the Dana Farber Cancer Institute between 2001–2015 with at least two
doses of carboplatin and docetaxel, the treatment demonstrated benefits for patients with germline
BRCA2 mutations [12]. Six out of the eight BRCA2 carriers identified (75%) presented a >50% PSA
decline within 12 weeks of initiating this regimen when compared to 23 of 133 of non-carriers (17%)
(p = 0.001). A >50% PSA decline was associated with a more prolonged survival (18.9 in BRCA2 carriers
vs. 9.5 months in non-carriers). Several studies are ongoing to evaluate the role of platinum-based
chemotherapy for patients with DNA repair defects.
Inhibition of the Poly ADP-ribose polymerase (PARP) is another strategy to treat DNA repair
deficient tumors as these drugs exploit the dependency of HR-deficient tumors on alternative DDR
pathways [35] and several PARP inhibitors are at different stages of clinical development (Table 3).
They differ in their potency and specificity to bind PARP and their ability to trap PARP-DNA
complexes [36]. Olaparib (AstraZeneca) was the first drug in class to be approved in 2014 for the
treatment of ovarian cancer associated with BRCA defects. The first-in-man clinical trial of olaparib
in a population of patients with advanced solid tumors, enriched for germline BRCA1 and BRCA2
mutations included three mCRPC patients; one of them benefited from the drug for over two years [37].
Small numbers of mCRPC patients with germline BRCA mutations were also enrolled in phase I trials
with other PARP inhibitors such as talazoparib [38] or niraparib as single agents [39].
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Table 2. Ongoing clinical trials evaluating PARP inhibitors in prostate cancer.
Clinical Trial Phase PARP Inhibitor Study Population DDR DefectsScreening Strategy Primary Endpoint
NCT02324998
(CaNCaP03) I Olaparib
Intermediate/High
Risk PCa Olaparib +/− Degarelix before radical prostatectomy
Determination of
PARP inhibition
NCT02861573
(KEYNOTE-365) I Olaparib mCRPC Cohort A: Pembrolizumab + Olaparib in post-docetaxel setting PSA50 response rate
NCT03317392 I/II Olaparib mCRPC Ra223 +/− Olaparib in mCRPC patients with bone metastases MTD of combinationand rPFS
NCT03787680
(TRAP trial) II Olaparib mCRPC Olaparib + ATR inhibitor (AZD6738) in second-line setting Response Rate
NCT03432897
(BrUOG 337) II Olaparib
Locally advanced
Prostate Cancer Olaparib prior to radical prostatectomy PSA response rate
NCT03012321 II Olaparib mCRPC Olaparib +/− Abiraterone/Prednisone in first-line setting PFS
NCT03434158
(IMANOL) II Olaparib mCRPC
Olaparib for patients who are responding after
docetaxel-chemotherapy rPFS
NCT03263650 II Olaparib AVPC Olaparib for patients who are responding after cabazitaxelplus carboplatin PFS
NCT03570476 II Olaparib Localized PCa Olaparib before radical prostatectomy pCR rate
NCT03047135 II Olaparib Biochemically-recurrentHigh-Risk PCa Olaparib in biochemically-recurrent prostate cancer PSA response rate
NCT03516812 II Olaparib mCRPC Olaparib + Testoterone Enanthate inpost-abiraterone/enzalutamide setting PSA50 response rate
NCT01682772
(TOPARP) II Olaparib mCRPC Olaparib in post-docetaxel setting Response Rate
NCT02893917 II Olaparib mCRPC Olaparib +/− Cediranib in second-line setting rPFS
NCT02987543
(PROfound) III Olaparib mCRPC Olaparib vs. Abiraterone or Enzalutamide in post-ASI setting rPFS
NCT03732820 III Olaparib mCRPC Abiraterone/Prednisone +/− Olaparib in first-line setting rPFS
NCT03076203
(NiraRad) I Niraparib mCRPC Niraparib + Radium-223 MTD
NCT03431350
(QUEST) I/II Niraparib mCRPC
Niraparib + Abiraterone/Prednisone or JNJ-63723283 in
post-ARSI setting
Incidence of toxicities
and ORR
NCT02854436
(Galahad) II Niraparib mCRPC Niraparib in Post-docetaxel and post-ARSI setting ORR
NCT03748641 III Niraparib mCRPC Abiraterone/Prednisone +/− Niraparib in first-line setting rPFS
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Table 3. Ongoing clinical trials evaluating PARP inhibitors in prostate cancer.
Clinical Trial Phase PARP Inhibitor Study Population DDR DefectsScreening Strategy Primary Endpoint
NCT03413995
(TRIUMPH) II Rucaparib mHSPC
Rucaparib without ADT (mHSPC without large lymph nodes
and visceral disease) PSA response rate
NCT02952534
(TRITON2) II Rucaparib mCRPC Rucaparib in Post-docetaxel and post-ARSI setting ORR
NCT03533946
(ROAR) II Rucaparib nmHSPC Rucaparib in nmHSPC with PSADT <10 months PSA50 response rate
NCT03338790
(CheckMate 9KD) II Rucaparib mCRPC Nivolumab + Rucaparib or Docetaxel or Enzalutamide ORR
NCT03442556 II Rucaparib mCRPC Rucaparib for patients who are responding afterdocetaxel plus carboplatin rPFS
NCT02975934
(TRITON3) III Rucaparib mCRPC
Rucaparib vs. Abiraterone/Enzalutamide/Docetaxel in
second-line setting rPFS
NCT03330405
(Javelin PARP
Medley)
II Talazoparib Locally advanced ormetastatic tumors Avelumab plus Talazoparib in advanced solid tumors DLT
NCT03148795
(TALAPRO-1) II Talazoparib mCRPC
Talazoparib in post-docetaxel and
post-abiraterone/enzalutamide setting ORR
NCT03395197
(TALAPRO-2) III Talazoparib mCRPC Enzalutamide +/− Talazoparib in first-line setting rPFS
DDR: DNA Damage Repair; PCa: Prostate Cancer; mCRPC: metastatic Castration Resistant Prostate Cancer; AVPC: Aggressive Variant Prostate Cancer; mHSPC: metastatic Hormone
Sensitive Prostate Cancer; nmHSPC: non-metastatic Hormone Sensitive Prostate Cancer; Ra223: Radium-223; ARSI: Androgen receptor signaling inhibitor (abiraterone, enzalutamide);
ADT: Androgen Deprivation Therapy; PSADT: PSA Doubling Time; PSA50 response: 50% reduction in PSA levels from baseline; MTD: Maximum Tolerate Dose; rPFS: radiographic
Progression-Free survival; PFS: Progression-Free Survival; pCR: pathologic Complete Response; ORR: Overall Response Rate; DLT: Dose Limiting Toxicities.
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An open-label single-arm basket phase II study of olaparib for germline BRCA mutation
carriers included eight mCRPC patients. Of these, one of four and three of four with or without
previous exposure to platinum, respectively, achieved a response to therapy [40]. The phase II trial
TOPARP-A [13] enrolled 50 men with heavily pre-treated mCRPC. Fourteen out of the 16 patients who
were found to harbor a DDR defect (somatic or germline) (88%) achieved clinical benefit (including
radiological responses, PSA drops, and/or CTC count decreases) and durable responses to the PARP
inhibitor olaparib including all seven patients with BRCA2 defects, but also some with BRCA1, ATM,
PALB2, and FANCA defects, among others. The preliminary results of the phase II trial TRITON2
evaluating the efficacy of rucaparib in a preselected population with DDR defects in tumor or ctDNA
showed PSA and radiographic responses in 48% and 45% of patients harboring BRCA2 defects.
Confirmed PSA and radiographic responses were also observed in one patient with BRIP1 and one
with FANCA mutations [41]. No confirmed responses were observed for ATM. This raises the question
of which DDR genes other than BRCA1 and BRCA2 may be considered predictive of response to PARP
inhibitors. However, this point may not be clarified until phase III trials are completed.
A cross-talk between the androgen receptor (AR) and DNA repair has been extensively
described [26,27,42]. First, PARP is involved in androgen dependent transcription and PARP inhibition
impairs this process [43]. Second, the androgen receptor regulates the transcription of DNA repair
genes and therefore androgen depletion impairs HR [26], so the tumor may become susceptible to
PARP inhibition regardless of HR mutation status. Supported by this preclinical data, several trials are
addressing the potential synergisms between PARP inhibitors and ARSIs, irrespective of DDR status.
The first study reported was NCI9012, a phase II trial that compared the efficacy of veliparib plus
abiraterone with abiraterone in monotherapy. No differences in PSA response rate (63.9% vs. 72.4%,
p = 0.27), radiographic response rate (45% vs. 52.2%, p = 0.51), or median PFS (10.1 vs. 11 months,
p = 0.99) were observed between the two groups, with all patients considered. However, 20 of the
148 (25%) patients included in the study had biallelic DDR defects and presented better PSA (90%
vs. 56%, p = 0.007) and radiographic (87.5 vs. 38.6, p = 0.001) response rates than the DDR-wild type,
in both treatment arms. The small number of DDR-defective patients in each treatment arm did not
allow further comparisons. The combination was well tolerated. Grade ≥3 side effects were observed
in 20% and 24% of the single and combination arms, respectively [44].
A second phase II randomized trial assessed the efficacy and tolerability of olaparib in combination
with abiraterone when compared with abiraterone in mCRPC patients, irrespective of their DDR status.
Eleven of 71 (15%) men in the olaparib arm and 10 out of 71 (14%) patients in the control arm had
mutations in the HR genes. However, 61% of patients only had partially characterized HR status
as the results of germline and plasma testing could not be confirmed by tumor analysis. Unlike the
previous study, time to radiographic progression was significantly prolonged in the olaparib plus
abiraterone group when compared to the abiraterone alone group (13.8 vs. 8.2, p = 0.034), regardless of
HR status. The study was not powered for subgroup analysis, but the exploratory analysis showed a
benefit on time to radiographic progression with the combination in patients with and without HR
defects. No differences in radiological response rates or in PSA responses were observed between the
two arms. Importantly, 54% of patients in the combination arm presented severe adverse events when
compared to 28% in the abiraterone group, including seven (10%) patients with a serious cardiovascular
event [45].
The contradictory results of these two studies regarding the benefit of adding a PARP inhibitor to
an ARSI in DDR-proficient patients to prolong the time to progression may be related to the different
pharmacological activity of veliparib and olaparib, but also to the different classification of patients by
DDR-status. Currently ongoing trials are likely to clarify this in the near future as well as whether the
benefit may outweigh the potential toxicity of the combinations (Table 3).
Unfortunately, resistance to PARP inhibitors eventually arises, even in patients with BRCA2
biallelic loss who usually present strong initial responses. Early reports suggest that subclonal
aberrations reverting germline and somatic DDR mutations back in frame may be a key mechanism of
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resistance [46,47]. Likewise, polyclonal BRCA2 reversion mutations have also been identified at the
time of disease progression in a patient treated with platinum-based chemotherapy [48]. In all cases,
these subclonal events likely driving resistance to PARP inhibitors and platinum, were identified in
circulating tumor DNA (ctDNA), reinforcing the clinical utility of ctDNA as a multipurpose biomarker
for treatment with PARP inhibition in mCRPC [47].
5. Implications for Hereditary Cancer and Germline Testing
Prostate cancer is one of the most heritable human cancers as 57% of the interindividual variation
in risk has been attributed to genetic factors [49]. Men harboring an inherited BRCA2 mutation have a
30% lifetime-risk of developing prostate cancer, although it may vary from 19% to 61% depending on
the presence/absence of genetic variants acting as risk-modifiers [50]. The impact of germline BRCA1
mutations is more modest as the life-time risk of prostate cancer associated with these mutations has
been estimated in 13% [50], similar to that of the general population. The prostate cancer risk for other
DDR genes beyond BRCA 1/2 remains unclear.
A Gleason score≥8, and nodal and distant metastasis at the time of diagnosis are more common in
BRCA carriers who develop prostate cancer than in non-carriers [8]. Despite the compelling evidence
indicating that BRCA2 mutations predispose carriers to an aggressive prostate cancer phenotype,
the most appropriate screening strategy has yet to be elucidated. International guidelines recommend
annual PSA-based prostate cancer screening from the ages between 40–45 [51]. The efficacy of this
approach is being analyzed in the IMPACT study. IMPACT is an international multicenter study that
has enrolled over 2000 men including 791 BRCA1 and 732 BRCA2 carriers aged 40–69 years. Participants
have annual PSA tests and the threshold to indicate a biopsy is a PSA >3 ng/mL. Data from the first
round of annual PSA screening have estimated the positive predictive value of PSA >3 ng/dL in 48%
for BRCA2 carriers, double than the 24% estimated for the general population [52]. Importantly, most
of the tumors in BRCA2 carriers identified through PSA in this preliminary report are of intermediate
or high risk unlike those detected through PSA screening in the general population, who are often
low-risk tumors [52]. However, considering the limitations of PSA-only screening in populations
at increased risk for prostate cancer, assessing the role of additional imaging and urine or blood
biomarkers in BRCA carriers would be important. The PRECISION study has demonstrated the value
of multiparametric magnetic resonance imaging (mpMRI) as a screening tool for prostate cancer [53]
and further studies should now assess if this more precise screening tool is of particular benefit for
men at an increased risk of aggressive prostate cancer due to inherited BRCA mutations.
Beyond prostate cancer, germline BRCA1 and BRCA2 mutations are known to increase the risk of
other tumor types including breast and ovarian cancers. More than 25 genes linked to DNA repair
have been associated with familial breast and/or ovarian cancers, most of them involved in HR and
Fanconi Anemia pathways [54]. Cancer patients who carry a germline mutation in one of these genes
often have other relatives also diagnosed with cancer, triggering genetic screening. However, studies
conducted in prostate cancer patients [3,4] have revealed that 30% of patients harboring a germline
mutation in a DDR gene and 15% of those who carry a BRCA2 mutation do not have a relative affected
by cancer. Although some reports suggest that intraductal histology may be common in patients
with germline BRCA2 mutations [55,56], no tumor features have been strongly associated with the
presence of BRCA mutations in prostate cancer beyond a Gleason score >8 and a higher prevalence of
node and distant metastasis at diagnosis [8]. Accordingly, updated National Comprehensive Cancer
Network clinical practice guidelines [24] now recommend clinicians consider germline screening for
mutations in BRCA2 and other HR genes in all patients with high risk localized prostate cancer and
metastatic disease. Identification of a germline mutation in a prostate cancer patient would not only
have implications for the patient, but should also be followed by genetic testing of all related family
members, providing the opportunity for early cancer-specific screening and risk reduction strategies
in those found to be carriers [57].
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Considering the high prevalence of prostate cancer in developed countries [58], the increasing
need for genetic testing, and the shortage of genetic counsellors, it is evident that the traditional
approach consisting of pre-test counselling is no longer feasible and new strategies to enable more
widespread access to genetic testing in a timely manner are needed. Some institutions are implementing
prostate cancer-focused genetic clinics alongside their pre-existing prostate cancer clinics. Under this
approach, patients eligible for testing may undergo counselling by a trained urologist or oncologist
managing the patient’s prostate cancer [59]. The ENGAGE study recently reported the results of the
oncologist-led BRCA testing in women with ovarian cancer and demonstrated efficient turnaround
times along with high levels of patient and physician satisfaction [60]. This could also be an adequate
and efficient strategy to counsel prostate cancer patients before undertaking a genetic test.
6. Conclusions and Future Directions
DDR defects are present in prostate cancer at a higher prevalence than previously recognized.
BRCA2 is the DDR gene most commonly mutated in advanced prostate cancer with up to 5.3% of these
patients carrying a germline mutation. Often, carriers lack a personal or family history of cancer to
suspect a heritable mutation, therefore germline screening should be considered in all patients with
advanced prostate cancer, at least until we are able to discern in which patients the likelihood of a
germline mutation is low enough to spare screening. Understanding the real prevalence of germline
DDR mutations in prostate cancer across populations would require further studies into screening
groups with different genetic backgrounds. Treating physicians are becoming aware of the clinical
implications of identifying these alterations and thanks to the more widespread access to genetic
testing, we are likely to obtain an accurate estimation of this prevalence in the near feature. Major
efforts are needed to guarantee the carriers’ access to a genetic counsellor in a timely manner as well
as to establish management protocols that improve these patient outcomes.
The approval of the PARP inhibitors to treat mCRPC patients with DDR defects is likely to occur
in the foreseeable future. Pending questions to be answered by currently ongoing trials are the benefit
of using PARP inhibitors at earlier disease stages either in monotherapy or in combination. However,
stratification of patients for PARP inhibition therapy by DDR defects is still suboptimal and represents
the major hurdle for the development of PARP inhibitors in this population. Each of the ongoing phase
II/III clinical trials testing the antitumor activity of PARP inhibitors and each laboratory performing
genetic diagnostic tests uses a different panel. Even more importantly, the analyses pipelines and the
criteria to classify genetic variants may differ significantly [61]. In addition, loss of function may occur
without changes in a gene sequence, but may be driven by other mechanisms including epigenetic
and transcriptomic changes. Assessing all the heterogeneous and complex mechanisms that could
lead to deficient DDR using the methodologies currently available is not cost-effective and we may
be under-identifying patients likely to benefit from PARP inhibitors. Further efforts are needed to
ascertain DDR deficiency in a comprehensive and efficient approach.
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